Invited Commentary: Treatment of Diseases of the Central Nervous System Using Encapsulated Cells, by A. F. Hottinger and P. Aebischer (Advances and Technical Standards in Neurosurgery Vol. 25)

  • A. E. Rosser
  • T. Ostenfeld
  • C. N. Svendsen
Part of the Advances and Technical Standards in Neurosurgery book series (NEUROSURGERY, volume 26)


The treatment of neurological disorders with conventional drug therapies, such as L-dopa for Parkinson’s disease, has traditionally been achieved by the administration of the drugs through peripheral routes. However, this approach is hampered by the problem of drug penetration across the blood brain barrier, as well as being relatively non-specific with respect to site of action within the CNS. The discovery of high molecular weight proteins which can affect the development of the CNS and protect against various types of neuronal cell death, has stimulated efforts to explore their use as neuroprotective agents in a variety of pathological conditions [3]. The direct delivery of these large peptides to the CNS can be achieved either by injection through an intracerebral cannula, which then communicates to the outside world, or by implantation of a closed system which has the capacity to continuously release the neuroactive substance. The advantages of an implantable system over pump injection are outlined by the authors and relate largely to practical issues such as the risk of infection associated with an indwelling cannula. Two main approaches have been employed in the development of implantable devices.


High Molecular Weight Protein Invite Commentary Encapsulate Cell Neuroactive Substance Peripheral Route 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Date I, Shingo T, Ohmoto T, Emerich DF (1996) Long-term enhanced chromaffin cell survival and behavioural recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells. Exp Neurol 147:10–17CrossRefGoogle Scholar
  2. 2.
    Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, Chu Y, McDermott P, Baetge EE, Kordower JH (1997) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s disease. Nature 386: 395–399PubMedCrossRefGoogle Scholar
  3. 3.
    Lindsay RM (1994) Neurotrophins and receptors. Prog Brain Res 103:3–14PubMedCrossRefGoogle Scholar
  4. 4.
    Mahoney MJ, Saltzman WM (1996) Controlled release of proteins to tissue transplants for the treatment of neurodegenerative diseases. J Pharm Sci 85:1276–1281PubMedCrossRefGoogle Scholar
  5. 5.
    Mittoux V, Joseph JM, Condé F, Palfi S, Zum A, Dautry C, Poyot T, Peschanski M, Aebischer P, and Hantraye P (1998) Encapsulated CNTF-producing fibroblasts reverse motor and cognitive deficits and protect striatal neurons in a chronic primate model of Huntington’s disease. Soc Neurosci Abstract 380.11Google Scholar
  6. 6.
    Sinclair SR, Svendsen CN, Torres EM, Martin D, Fawcett JW, Dunnett SB (1996) GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 7:2547–2552PubMedCrossRefGoogle Scholar
  7. 7.
    Winn SR, Lindner MD, Lee A, Haggett G, Francis JM, Emerich DF (1996) Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences. Exp Neurol 140:126–138PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2000

Authors and Affiliations

  • A. E. Rosser
    • 1
  • T. Ostenfeld
    • 1
  • C. N. Svendsen
    • 1
  1. 1.The Cambridge Centre for Brain RepairCambridgeUK

Personalised recommendations